<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 45-year-old woman presents to the clinic for a routine examination. She has a chronic history of systemic lupus erythematosus, diagnosed at age 27. Medications include hydroxychloroquine and low-dose prednisone. She has had no recent flare-ups and is compliant with her medication. Anticardiolipin and anti-beta-2 glycoprotein-1 antibodies are negative, and she has had no history of thrombi or emboli. Physical examination is normal except for mild bilateral tenderness and swelling of the knees. Creatinine and GFR are normal. Which of the following is the next best step in management to monitor disease activity?? A: Urinalysis and renal biopsy, B: Anti-dsDNA antibody levels, C: Anti-Smith antibody levels, D: Reduce dosage and taper off hydroxychloroquine, E: Arthrocentesis and synovial fluid analysis,  <response>: This is a question about monitoring disease activity in a patient with systemic lupus erythematosus SLE. The patient has a history of SLE diagnosed at age 27 and is on maintenance therapy with hydroxychloroquine and low-dose prednisone. She has no recent flare-ups. On exam, she has mild knee swelling and tenderness which could indicate arthritis, a common manifestation of SLE. Creatinine and GFR are normal ruling out lupus nephritis. The correct next step would be a test to evaluate disease activity rather than a change in therapy. Anti-dsDNA antibodies are associated with disease activity in SLE. A positive result would indicate a disease flare. The other answers do not directly assess disease activity.B: Anti-dsDNA antibody levels 